Recombinant Human Aldo-Keto Reductase Family 1 Member B10 (AKR1B10) Protein (GST)

Name: Recombinant Human Aldo-Keto Reductase Family 1 Member B10 (AKR1B10) Protein (GST)
Brand: Beta LifeScience
SKU: BLC-09139P
Availability: InStock

Greater than 90% as determined by SDS-PAGE.

Collections: All products, High-quality recombinant proteins, Other recombinant proteins

Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description	Recombinant Human Aldo-Keto Reductase Family 1 Member B10 (AKR1B10) Protein (GST) is produced by our E.coli expression system. This is a full length protein.
Purity	Greater than 90% as determined by SDS-PAGE.
Uniprotkb	O60218
Target Symbol	AKR1B10
Synonyms	AK1BA_HUMAN; AKR1B10; AKR1B11; AKR1B12; Aldo keto reductase family 1 member B10; aldo keto reductase family 1 member B11; Aldo-keto reductase family 1 member B10 (aldose reductase); Aldo-keto reductase family 1 member B10; Aldo-keto reductase family 1 member B11 (aldose reductase-like); aldose reductase like 1; Aldose reductase like; aldose reductase like peptide; Aldose reductase related protein; Aldose reductase-like; Aldose reductase-related protein; ALDRLn; ARL 1; ARL-1; ARL1; ARL1 Human small intestine reductase; ARP; hARP; HIS; HSI; SI reductase; Small intestine reductase
Species	Homo sapiens (Human)
Expression System	E.coli
Tag	N-GST
Target Protein Sequence	MATFVELSTKAKMPIVGLGTWKSPLGKVKEAVKVAIDAGYRHIDCAYVYQNEHEVGEAIQEKIQEKAVKREDLFIVSKLWPTFFERPLVRKAFEKTLKDLKLSYLDVYLIHWPQGFKSGDDLFPKDDKGNAIGGKATFLDAWEAMEELVDEGLVKALGVSNFSHFQIEKLLNKPGLKYKPVTNQVECHPYLTQEKLIQYCHSKGITVTAYSPLGSPDRPWAKPEDPSLLEDPKIKEIAAKHKKTAAQVLIRFHIQRNVIVIPKSVTPARIVENIQVFDFKLSDEEMATILSFNRNWRACNVLQSSHLEDYPFNAEY
Expression Range	1-316aa
Protein Length	Full Length
Mol. Weight	63.0kDa
Research Area	Signal Transduction
Form	Liquid or Lyophilized powder
Buffer	Liquid form: default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
Reconstitution	Briefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. The default final concentration of glycerol is 50%.
Storage	1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C.
Notes	Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.

Target Details

Target Function	Catalyzes the NADPH-dependent reduction of a wide variety of carbonyl-containing compounds to their corresponding alcohols. Displays strong enzymatic activity toward all-trans-retinal, 9-cis-retinal, and 13-cis-retinal. Plays a critical role in detoxifying dietary and lipid-derived unsaturated carbonyls, such as crotonaldehyde, 4-hydroxynonenal, trans-2-hexenal, trans-2,4-hexadienal and their glutathione-conjugates carbonyls (GS-carbonyls). Displays no reductase activity towards glucose.
Subcellular Location	Lysosome. Secreted. Note=Secreted through a lysosome-mediated non-classical pathway.
Protein Families	Aldo/keto reductase family
Database References	HGNC: 382 OMIM: 604707 KEGG: hsa:57016 STRING: 9606.ENSP00000352584 UniGene: PMID: 30328412 These results suggest that AKR1B10 is involved in HBV-related hepatocarcinogenesis, but its high expression could predict low risk of early tumor recurrence in patients with HBV-related hepatocellular carcinoma (HCC)after liver resection. PMID: 28181486 AKR1B10 is upregulated in mucinous cystic pancreatic tumors and may be used to improve non-operative diagnosis. PMID: 29079172 A combined gene expression signature of AKR1B10 (low) and AKR1B1 (high) showed a better prognostic stratification of CRC patients independent of confounding factors. PMID: 28929377 Our study demonstrated not only the dysfunction of the AKR1B10 gene in lipid metabolizing but also its important role in the overproliferation and migration of keratinocyte, which provided evidence for further therapeutic uses for psoriasis. PMID: 29204449 Data show that cells with higher levels of aldo-keto reductases AKR1B1 and/or AKR1B10 (AKR1Bs) were more sensitive to 2-deoxyglucose (2DG). PMID: 29617059 Results demonstrate that Akr7a3 mRNA and protein levels are consistently co-expressed along with Akr1b10, in both experimental rat liver carcinogenesis and some human hepatocellular carcinoma samples. PMID: 29383608 AKR1B10 overexpression is an independent poor prognostic biomarker for oral squamous cell carcinoma. PMID: 28301069 These data suggest that AKR1B10 promotes breast cancer metastasis PMID: 27248472 Several antioxidant response elements-like sequences in the 5'-flanking region up to -3282 bp of the AKR1B10 gene plays an important role in AKR1B10 gene regulation by various Nrf2-mediating stimuli. PMID: 28219640 This study presents novel evidence that AKR1B10 protects colon cells from DNA damage induced by electrophilic carbonyl compounds. PMID: 26969882 the highly efficient, retinaldehyde-specific aldo-keto reductase enzyme AKR1B10 is up-regulated in keloid epidermis(KE) and its induced overexpression in normal skin keratinocytes affects the classical RA pathway, recreating KE expression patterns PMID: 27025872 Data suggest that expression of STAR (steroidogenic acute regulatory protein) and AKR1B10 (aldo-keto reductase family 1, member B10) is down-regulated in high-grade versus low-grade endometrial tumors; expression of AKR1B10 correlates with body mass index, with up-regulation of expression of AKR1B10 in obese patients with endometrial tumors. PMID: 28232277 Result indicate that the differential scanning fluorimetry (DSF) method is useful for enzyme inhibitor drug screening for the AKR superfamily, including AKR1B10 and a structurally similar isoform AKR1B1. PMID: 28003428 Chronic hepatitis C patients expressing high levels of hepatic AKR1B10 had an increased risk of HCC development even after sustained virological response PMID: 27672277 Various degrees of AKR1B10 upregulation in the liver were observed in patients with chronic HCV infection, and high AKR1B10 expression could be a novel pre- dictor of HCC. PMID: 26758591 AKR1B10 is up-regulated with cisplatin resistance in gastrointestinal cancer cells. PMID: 27417252 AKR1B10 mRNA and protein levels were higher in primary hepatocellular carcinoma (PHC) tissues than in peri-tumor tissues. PMID: 26948042 AKR1B10 is overexpressed in nasopharyngeal hyperplasia, benign tumors, and carcinomas, being a potential new biomarker. PMID: 26835713 Even at early stages of malignant transformationa considerable increase in AKR1B10 mRNA content was observed in 80% of tumors PMID: 27239845 It would appear that hepatitis C virus infection alone increases AKR1B10 expression, which manifests itself as enhanced urinary excretion of polyols with reduced urinary excretion of their corresponding hexoses. PMID: 25487531 Our data suggest that genetic variants in the AKR1B10 locus may influence human eating behavior. PMID: 25887478 The three-dimensional structure of AKR1B10 with sulindac. PMID: 25532697 The co-introduction of the c-Jun protein resulted in a decrease in the mRNA levels and promoter activity of AKR1B10. PMID: 25463304 Autophagy and AKR1B10 contribute to the defense system. PMID: 25289770 AKR1B10 is a doxorubicin-resistance gene in the gastric cancer cells, and is responsible for elevating the migrating and invasive potentials of the cells through induction of MMP2. PMID: 25686905 Upregulation of AKR1B10 is associated with cisplatin resistance in lung cancer. PMID: 25156503 AKR1B10 is a unique enzyme involved in pancreatic carcinogenesis via modulation of the Kras-E-cadherin pathway. PMID: 25304374 AKR1B10 may have an important role in the development and progression of diabetic nephropathy. PMID: 23975544 A significant correlation between the expression of AKR1B10 mRNA and protein levels as well as AKR1B10 copy number was observered, which suggest that AKR1B10 may play a role in AFB1-related hepatocarcinogenesis. PMID: 24391771 Results suggest that decreased expression of AKR1B10 could disrupt the tumor suppressive function of p53, which result in decreased survival in colorectal cancer patients. PMID: 24140838 AKR1B10, a member of Aldo-keto reductase family, was shown to be abundantly located in the filtering cells among a catalog of proteins.in ducal carcinoma of the breast. PMID: 23912490 AKR1B10 is a unique biomarker involved in hepatocellular carcinogenesis PMID: 24656094 AKR1B10 protein gene expression is a valuable indicator in patients diagnosed with gastric cancer. PMID: 24406159 Lys-233, Glu-236, and Lys-240 in helix 10 mediate interaction of AKR1B10 with HSP90alpha and regulate AKR1B10 secretion. PMID: 24217247 A hydrogen bond stabilized active site tryptophan conformation restricts inhibitor access in AKR1B1 compared with the more open AKR1B10 active site. PMID: 24100137 our data suggest that post-chemotherapy AKR1B10 expression may be associated with a poor prognosis in patients who received carboplatin-gemcitabine combination chemotherapy and underwent cystectomy PMID: 22198799 The gene expression of AKR1B10 at the mRNA level was significantly increased. PMID: 23146748 AKR1B10 was the most efficient catalyst of the stoichiometric two-electron reduction of BQ. PMID: 22498646 AKR1B10 was up-regulated in association with serum alpha-fetoprotein, and was an independent risk factor for hepatocellular carcinoma in chronic hepatitis C patients. PMID: 22681639 AKR1B10 is a unique enzyme involved in pancreatic carcinogenesis possibly via modulation of cell apoptosis and protein prenylation. PMID: 22222635 results suggest that AKR1B10 is up-regulated by EGF and insulin through AP-1 mitogenic signalling and may be implicated in hepatocarcinogenesis PMID: 22329800 AKR1B10 overexpression is a prominent feature in both hereditary and sporadic papillary renal cell carcinoma and is upregulated in cell lines carrying a fumarate hydratase mutation. PMID: 22014576 AKR1B10 might promote proliferation, inhibit apoptosis and induce malignant transformation of hepatocytes by regulating the expression level of some tumor-related genes. PMID: 20943077 Confirm prognostic value of AKR1B10 in hepatocellular carcinoma and conclude that high expression reflects less aggressive tumour behaviour. PMID: 21645211 High AKR1B10 secretion is associated with neoplasms. PMID: 21585341 AKR1B10 is associated with smoking and smoking-related non-small-cell lung cancer. PMID: 21672310 the enzyme activity of AKR1B10 and AKR1B1 toward alpha, beta-unsaturated carbonyl compounds with cellular and dietary origins PMID: 21329684 Nrf2 is one of the major factors involved in the AKR1B10 gene regulation PMID: 21277289 overexpression and silencing of AKR1B10 decreased and increased, respectively, susceptibility to cytotoxic effects of MMC and 4-hydroxy-2-nonenal, which was formed as a product of lipid peroxidation by MMC treatment. PMID: 21317765

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.